Fig. 5From: Endotype-driven treatment in chronic upper airway diseasesBarrier dysfunction and potential biomarkers. EGF epidermal growth factor; EGF-R epidermal growth factor receptor; JAM-A junctional adhesion molecule A; TLR toll-like receptor; ZO zona occludensBack to article page